Hikma Pharmaceuticals USA Inc.

Form 483 issued September 10, 2019 · Cherry Hill, New Jersey

Inspection
Sep 10, 2019
Investigator
Win B. Hii
Observations
4
Pages
2
FEI number
2220525

In short: On September 10, 2019, FDA issued a Form 483 with 4 observations to Hikma Pharmaceuticals USA Inc. in Cherry Hill, New Jersey (FEI 2220525) after an inspection that ran Sep 10, 2019. The investigator was Win B. Hii. Most observations concern laboratory controls and quality system.

At a glance

Observations span 4 systems, led by laboratory controls.

Laboratory controls1
Quality system1
Records & documents1
Design controls1

What FDA observed

Preview: the opening words of each observation

Dashed: section inferred by FDA Intel and checked against the regulation text

  1. 01

    Stability data does not support the…

  2. 02

    There is a failure to thoroughly review the failure of a batch or any of its…

  3. 03

    A device history record has…

  4. 04

    Procedures for design review…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Hikma Pharmaceuticals USA Inc.?

FDA listed 4 observations on this Form 483, mostly about laboratory controls, quality system and records & documents. The opening words of each observation are shown on this page.

Who inspected Hikma Pharmaceuticals USA Inc.?

Win B. Hii is named on this Form 483, for the inspection of Sep 10, 2019. Each investigator has a profile showing what they cite most.

When was Hikma Pharmaceuticals USA Inc. inspected by FDA?

The inspection ran Sep 10, 2019, and the Form 483 is dated September 10, 2019.

How do I get the full Form 483 for Hikma Pharmaceuticals USA Inc.?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free